Kang-Yi Su Selected Research

Therapeutics

1/2021	Primary Tumor Resection Is Associated with a Better Outcome among Advanced EGFR-Mutant Lung Adenocarcinoma Patients Receiving EGFR-TKI Treatment.
1/2019	High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients.
10/2018	The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma.
11/2017	EGFR mutation, smoking, and gender in advanced lung adenocarcinoma.
8/2016	Higher frequency but random distribution of EGFR mutation subtypes in familial lung cancer patients.
1/2016	Implementation and Quality Control of Lung Cancer EGFR Genetic Testing by MALDI-TOF Mass Spectrometry in Taiwan Clinical Practice.
4/2015	Dynamic plasma EGFR mutation status as a predictor of EGFR-TKI efficacy in patients with EGFR-mutant lung adenocarcinoma.
1/2015	HOXA5 inhibits metastasis via regulating cytoskeletal remodelling and associates with prolonged survival in non-small-cell lung carcinoma.
1/2015	Identification of five driver gene mutations in patients with treatment-naïve lung adenocarcinoma in Taiwan.
8/2014	Shisa3 is associated with prolonged survival through promoting β-catenin degradation in lung cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kang-Yi Su Research Topics

Disease

27	Neoplasms (Cancer) 10/2023 - 09/2006
22	Adenocarcinoma of Lung 11/2023 - 04/2011
14	Lung Neoplasms (Lung Cancer) 11/2023 - 04/2011
12	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2023 - 02/2012
7	Neoplasm Metastasis (Metastasis) 11/2023 - 11/2012
4	Adenocarcinoma 01/2020 - 10/2017
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 10/2017 - 01/2016
2	Carcinogenesis 08/2014 - 09/2006
1	Shock 01/2022
1	Sepsis (Septicemia) 01/2022
1	Major Depressive Disorder (Major Depressive Disorders) 08/2021
1	Colonic Neoplasms (Colon Cancer) 06/2020
1	Colorectal Neoplasms (Colorectal Cancer) 06/2020
1	Invasive Fungal Infections 01/2019
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 11/2018
1	Liver Diseases (Liver Disease) 01/2018
1	Non-alcoholic Fatty Liver Disease 01/2018
1	Disease Progression 01/2018
1	Melanoma (Melanoma, Malignant) 10/2017
1	Tuberculosis (Tuberculoses) 01/2017
1	Testicular Neoplasms (Testicular Cancer) 07/2016
1	Lymphoma (Lymphomas) 04/2016
1	Stroke (Strokes) 01/2016
1	Cerebral Infarction 01/2016
1	Ischemia 01/2016
1	Liver Cirrhosis (Hepatic Cirrhosis) 04/2014
1	Fibrosis (Cirrhosis) 04/2014
1	Inflammation (Inflammations) 01/2014
1	Fatigue 01/2014

Drug/Important Bio-Agent (IBA)

23	ErbB Receptors (EGF Receptor)IBA 11/2023 - 04/2011
18	Tyrosine Kinase InhibitorsIBA 04/2022 - 04/2011
7	osimertinibIBA 01/2023 - 01/2018
5	Biomarkers (Surrogate Marker)IBA 11/2023 - 01/2014
5	Proteins (Proteins, Gene)FDA Link 01/2023 - 09/2006
4	DNA (Deoxyribonucleic Acid)IBA 10/2023 - 04/2015
3	AfatinibIBA 01/2023 - 01/2022
3	B7-H1 AntigenIBA 01/2022 - 01/2020
3	LigandsIBA 01/2022 - 07/2018
2	MicroRNAs (MicroRNA)IBA 10/2023 - 01/2023
2	Gefitinib (Iressa)FDA Link 04/2022 - 04/2011
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 04/2022 - 01/2014
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 01/2017
2	AntigensIBA 10/2017 - 07/2016
2	Propolis (Bee Bread)IBA 01/2016 - 04/2014
2	FlavonoidsIBA 01/2016 - 01/2014
2	Messenger RNA (mRNA)IBA 01/2016 - 04/2011
2	hepsinIBA 11/2012 - 09/2006
1	AdipokinesIBA 11/2023
1	C-Reactive ProteinIBA 11/2023
1	CytokinesIBA 11/2023
1	ProteomeIBA 01/2023
1	Bevacizumab (Avastin)FDA Link 04/2022
1	Heat-Shock Proteins (Heat-Shock Protein)IBA 01/2022
1	LipopolysaccharidesIBA 01/2022
1	Interleukin-12 (IL 12)IBA 01/2022
1	InterferonsIBA 01/2022
1	Molecular Chaperones (Chaperone, Molecular)IBA 01/2022
1	exodeoxyribonuclease IIBA 01/2022
1	EndotoxinsIBA 01/2022
1	Prealbumin (Transthyretin)IBA 08/2021
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 06/2020
1	Calcibiotic Root Canal SealerIBA 06/2020
1	CrizotinibIBA 01/2020
1	Anaplastic Lymphoma KinaseIBA 01/2020
1	TriazolesIBA 01/2019
1	Voriconazole (Vfend)FDA LinkGeneric 01/2019
1	SynaptophysinIBA 11/2018
1	Retinoblastoma ProteinIBA 11/2018
1	Chromogranin AIBA 11/2018
1	Phosphotransferases (Kinase)IBA 10/2018
1	Transcription Factors (Transcription Factor)IBA 01/2018
1	Cell-Free Nucleic AcidsIBA 01/2018
1	NivolumabIBA 01/2018
1	pembrolizumabIBA 01/2018
1	FructoseIBA 01/2018
1	Neoplasm Antigens (Tumor Antigens)IBA 10/2017
1	NucleotidesIBA 01/2017
1	SaltsIBA 04/2016
1	Small Interfering RNA (siRNA)IBA 01/2016
1	RNA (Ribonucleic Acid)IBA 01/2016
1	Terpenes (Terpenoids)IBA 01/2016
1	Nucleic AcidsIBA 04/2015
1	Peptide Nucleic AcidsIBA 04/2015
1	OligonucleotidesIBA 01/2015
1	CateninsIBA 08/2014
1	propolin GIBA 04/2014
1	Alanine Transaminase (SGPT)IBA 04/2014
1	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 01/2014
1	Advanced Glycation End ProductsIBA 01/2014
1	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 01/2014
1	PlatinumIBA 01/2014
1	Rutin (Rutoside)IBA 01/2014
1	Superoxide DismutaseIBA 01/2014
1	Malondialdehyde (Propanedial)IBA 01/2014
1	GlycogenIBA 01/2014
1	Glutathione PeroxidaseIBA 01/2014
1	EnzymesIBA 01/2014

Therapy/Procedure

12	Therapeutics 01/2021 - 01/2013
4	Immunotherapy 01/2023 - 01/2018
1	Aftercare (After-Treatment) 01/2018